Guggenheim Initiates Coverage On Rapport Therapeutics with Buy Rating, Announces Price Target of $65
Guggenheim analyst Delma Caiati initiates coverage on Rapport Therapeutics (NASDAQ:RAPP) with a Buy rating and announces Price Target of $65.
Stocks · News reference
8-K filing — Rapport Therapeutics, Inc. (RAPP)
Filed: 2026-08-05 AccNo: 0001193125-26-333853 Size: 464 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Rapport Therapeutics To Rally Around 76%? Here Are 10 Top Analyst Forecasts For Wednesday
Analysts raised targets for RAPP, ALLR, UNP and ALVO; cut targets for NU, CLLS and JBHT, with several rating upgrades and downgrades.
BTIG Maintains Buy on Rapport Therapeutics, Raises Price Target to $75
BTIG analyst Kambiz Yazdi maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and raises the price target from $65 to $75.
BTIG Reiterates Buy on Rapport Therapeutics, Maintains $65 Price Target
BTIG analyst Kambiz Yazdi reiterates Rapport Therapeutics (NASDAQ:RAPP) with a Buy and maintains $65 price target.